Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review by Mori, Amani Thomas & Robberstad, Bjarne
Mori and Robberstad BMC Medical Informatics and Decision Making 2012, 12:110
http://www.biomedcentral.com/1472-6947/12/110RESEARCH ARTICLE Open AccessPharmacoeconomics and its implication on
priority-setting for essential medicines in
Tanzania: a systematic review
Amani Thomas Mori1,2* and Bjarne Robberstad1Abstract
Background: Due to escalating treatment costs, pharmacoeconomic analysis has been assigned a key role in the
quest for increased efficiency in resource allocation for drug therapies in high-income countries. The extent to
which pharmacoeconomic analysis is employed in the same role in low-income countries is less well established.
This systematic review identifies and briefly describes pharmacoeconomic studies which have been conducted in
Tanzania and further assesses their influence in the selection of essential medicines.
Methods: Pubmed, Embase, Cinahl and Cochrane databases were searched using “economic evaluation”,
“cost-effectiveness analysis”, “cost-benefit analysis” AND “Tanzania” as search terms. We also scanned reference lists
and searched in Google to identify other relevant articles. Only articles reporting full economic evaluations about
drug therapies and vaccines conducted in Tanzania were included. The national essential medicine list and other
relevant policy documents related to the identified articles were screened for information regarding the use of
economic evaluation as a criterion for medicine selection.
Results: Twelve pharmacoeconomic studies which met our inclusion criteria were identified. Seven studies were on
HIV/AIDS, malaria and diarrhoea, the three highest ranked diseases on the disease burden in Tanzania. Six studies
were on preventive and treatment interventions targeting pregnant women and children under the age of five
years. The national essential medicine list and the other identified policy documents do not state the use of
economic evaluation as one of the criteria which has influenced the listing of the drugs.
Conclusion: Country specific pharmacoeconomic analyses are too scarce and inconsistently used to have had a
significant influence on the selection of essential medicines in Tanzania. More studies are required to fill the
existing gap and to explore whether decision-makers have the ability to interpret and utilise pharmacoeconomic
evidence. Relevant health authorities in Tanzania should also consider how to apply pharmacoeconomic analyses
more consistently in the future priority-setting decisions for selection of essential medicines.
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Pharmacoeconomic analysis is the comparison of costs
and consequences of alternative drug therapies so as to
maximize therapeutic outcomes when resources are lim-
ited. Use of pharmacoeconomics is important in
priority-setting between drug therapies since budgets
are finite and there is great variance in value for money
for products in the market. Some products are more
costly but add little or no extra benefits when compared
to the existing drug therapies. In other situations new
and more expensive drugs represent large potential
health improvements. Pharmacoeconomic evidence can
help decision-makers judge whether the therapeutic
benefits produced by a new drug are worth the extra
costs [1].
In high-income countries pharmacoeconomic analysis
is widely used to guide priority-setting decisions for
pharmaceuticals [2]. National Institute of Clinical Excel-
lence (NICE) in the UK and the Canadian Agency for
Drugs and Technology in Health (CADTH) are exam-
ples of institutions which have been established for phar-
macoeconomic evaluation of new pharmaceutical
products and technologies [3,4]. Pharmacoeconomic
evaluation has also gained acceptance at hospital level in
formulary decision-making in these countries [5]. By
contrast, in low-income countries applied economic
evaluation studies are not only scarce, but their useful-
ness on essential medicine selection has also been
debated in the literature [6,7].
Essential medicines are those which address priority
healthcare needs of the populations. Since its inception,
the concept of essential medicines aims to increase avail-
ability and accessibility of medicines in low-income
countries [8]. The strategy was consolidated in the Alma
Ata conference where access to essential medicines was
listed as one of the key component of the primary
healthcare package [9]. Increase in access to high quality
essential medicines is today viewed as the most import-
ant global strategy to reduce the burden of diseases [10].
This strategy is of particular importance for low-income
countries which carry a disproportionately large share of
the disease burden [11], but yet are accounted for as lit-
tle as one per cent of the total global pharmaceutical
expenditures [12].
Tanzania had its first national essential medicine list in
1991, while the current edition of 2007 is the third in
the series. The national essential medicine list is consid-
ered to be in line with the WHO recommendations
under the Tanzania conditions [13]. WHO proposed the
use of evidence-based approach in the selection process
of essential medicines, with cost-effectiveness compari-
sons being one of the key criteria [14]. Little country
specific cost-effectiveness evidence is available for
Tanzania [15], which raises questions on whether, howand to what extent such evidence is actually used to
guide priority-setting decisions. Therefore this system-
atic review aims to identify and briefly describe pharma-
coeconomic studies which have been conducted in
Tanzania and assess their influence on the priority-
setting process for selection of essential medicines.
Methods
We used the PRISMA checklist which is suited for
reporting systematic review of randomized trials but also
recommended for other systematic review studies [16].
Some modifications were done to adopt the checklist to
report economic evaluation studies.
Information sources
Pubmed and Cinahl databases were searched for all
years, limiting the search to English language using the
combinations of the following search terms: “economic
evaluations”, “cost-effectiveness analysis”, “cost-benefit
analysis” AND “Tanzania”. Cochrane library was
searched using the key word “Tanzania” in its NHS eco-
nomic evaluation databases, and using “cost-
effectiveness analysis” AND “Tanzania” in its Cochrane
Control Register of Controlled Trials Database. Embase
was searched from 1980 to 2011(week 51) limiting the
search to English language and “Human”. “Economic
evaluations” AND “Tanzania”, “cost-effectiveness ana-
lysis” AND “Tanzania” and “cost-benefit analysis” AND
“Tanzania” were used as search terms. Last search of
these databases was 30th December 2011. Other articles
were identified by scanning reference lists and searching
by Google search engine using the above mentioned
search terms.
The Tanzanian national essential medicine list and
other relevant policy documents related to the identi-
fied articles were also screened for information related
to the use of economic evaluation evidences as a criter-
ion for the selection of the recommended medicines.
Also we aimed to determine whether the medicines
listed in these policy documents were similar to those
recommended by the authors of the articles we had
identified.
Study selection criteria and rationales
Inclusion criteria
1. Study design: economic evaluation since the aim was
to compare costs and outcomes of alternative
interventions competing for the same resources
2. Study interventions: drug therapies or vaccines only
since these are the ones listed on treatment
guidelines and national essential medicine list
3. Study setting: Tanzania
4. Publication type: Original full articles or reports
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1. Economic evaluation studies of the methods used to
distribute the drugs or vaccines to the patients since
this was not our study focus
2. Studies presenting only costs or only effectiveness
results since they provide insufficient information
required for cost-effectiveness assessment
3. Hypothetical interventions since they do not
represent actual intervention strategies
4. Review articles since they contain information
extracted from individual studies already included
Each article was initially screened based on its title
and the abstract to see whether it met our inclusion and
exclusion criteria. Articles which passed the screening
stage were subjected to full text assessment for eligibil-
ity. Eligible articles were selected for the qualitative
analysis.
Data extraction procedure
Necessary information such as names of the authors,
publication year, the target intervention, study perspec-
tives and the recommended drug therapies and their
cost-effectiveness ratios were extracted from each of the
twelve articles. Ranking of the disease burden was
extracted from the Tanzania national package of theFigure 1 Flow of information through the different phases of the sysessential health interventions. Generic names of the
recommended drugs and vaccines and the rationales be-
hind them, were extracted from the national essential
medicine list and other relevant policy documents.
Results
Study selection
396 articles were retrieved from various databases and
other sources in which 72 were excluded because they
were duplicate hits. The remaining 324 unique articles
were screened by titles and abstracts after which 309
articles were excluded. Three articles out of the
remaining 15 were excluded because one was a brief
communication [17], the second was about a hypothet-
ical malaria vaccine [18], and the third was a review
study [19]. Therefore only 12 full articles qualified for
the qualitative analysis [20-31] (Figure 1).
Burden of diseases versus availability of
pharmacoeconomic studies
Tanzania has a list of twelve priority disease conditions
referred to as a national package of essential health
interventions, on which to prioritize the allocation of its
scarce resources for health. This list rank disease condi-
tions according to their burden of disease and is domi-
nated by infectious diseases – HIV/AIDS, malaria and
diarrhoeal diseases are at the top. Ranking of the diseasetematic review.
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macoeconomic studies we have identified. Nine out of
the twelve pharmacoeconomic analysis studies addresses
the four highest ranked disease conditions (Table 1) It isTable 1 Disease burden rank, pharmacoeconomic evidences a
status
Rank Disease Tanzanian
pharmacoeconomic
evidence
Main findings,
1 HIV/AIDS HAART for PMTCT [21] Highly cost-effe
compared to sd
( Listing status:
one being imple
Sd-NVP for PMTCT [24] (Listing status: U
recommendatio
2 Malaria ALu for non-severe
malaria [26]
A cost-effective
amodiaquine. (
therapies recom
SP for non-severe
malaria [25]
(Listing status: U
resistance but st
SP for IPTi [27] A cost-effective
reduces episod
moderate to hi
(Listing status: S
since 2010 but n
3 Diarrhoeal diseases Zinc as adjunct
therapy [23]
A highly cost-e
ICER of US$ 73
(Listing status: L
WHO’s recomm
4 Injury/ Trauma Tranexamic acid Inj for
surgical bleeding and
trauma patients [20,29]
A highly cost-e
for surgical and
and volume of
risks of death b
(Listing status: T
medicine but no
5 ARI None None
6 TB Short-course
chemotherapy [31]
A highly cost-e
chemotherapy
(Listing status: L
7 Prenatal conditions None None
8 Maternal deficiencies None None
9 Nutritional deficiencies Iron+ Deltaprim to
prevent anaemia and
malaria in infants [28]
Considered to
SP-IPTi in reduc
(Listing status: D
medicine in Tan
10 CVD and Diabetes Preventive cardiology
[22]
Diuretics, Aspiri
ICERS of US$ 85
(Listing status: n
before the publi
11 Neoplasms None None
12 Immunisable diseases Anti-Rabies vaccine
[30]
A very cost-effe
provider and so
(Listing status: N
before the publi
* Compared to do nothing, ALu-artemether-lumefantrine, SP- sulphadoxine-pyrimet
rehydration salt, ARI-acute respiratory tract infections, CVD-cardiovascular diseases.disappointing to note that only one pharmacoeconomic
study addresses non-communicable diseases, and none
are available for acute respiratory tract infections, dia-
betes, cancers, and nutritional deficiencies.nd their main findings, implications and current listing
implications and current listing status
ctive intervention with ICER of US$ 162 per DALY averted when
-NVP, however it is 40% more costly but 5 times more effective
HAART is one of the two options recommended by WHO but not the
mented in Tanzania, an area for future research)
se of Sd-NVP is the old policy which was also based on WHO’s
ns but currently being phased out in Tanzania)
drug which saves US$ 22.4 per case averted when compared to
Listing status: ALu is one of the few artemisinin-based combination
mended by WHO and is the current drug of choice in Tanzania)
se of SP was replaced by ALu since 2007 due to parasite
ill listed as essential medicine for IPTp)
intervention with ICER of US$ 1.6-12.2 per DALY* averted. SP-IPTi
es of clinical malaria and anaemia by 30 and 21 percent in areas of
gh malaria transmissions, in the first year of life [32].
P-IPTi is a new intervention strategy recommended by WHO
ot yet adopted in Tanzania)
ffective intervention when combined with ORS with
per DALY averted
isted on essential medicine list since 2007, based on
endations)
ffective intervention with ICER of US$ 93 and US$ 48 per life saved
trauma patients*. TXA reduces number of transfusions by one-third
blood per transfusion by one unit in elective surgery [33]. TXA reduces
y 21% if administered within 3 hrs after injury [34].
ranexamic acid Inj. was listed recently on WHO’s list of essential
t yet listed in Tanzania)
ffective option with ICER of US$ 1–4 per LY saved. Short-course
increases cure rate by 25% compared to the long regimens.
isted; Introduced and adopted in Tanzania in mid 1980’s)
be a cost-effective intervention, support the evidence shown by
tion of both anaemia and malaria
eltaprin (dapsone +pryrimethamine) is not listed as essential
zania
n+Diuretic and Aspirin+Diuretic+β-blocker are very cost-effective with
, 143 and 317 per DALYS averted.
ew evidence but these drugs were already listed as essential medicines
cation of the study)
ctive intervention with ICER of US$ of 27 and 32 per DALY* averted from
cietal perspectives.
ew evidence, but the vaccine was already listed as essential medicine
cation of the study)
hamine, Sd-Single dose, HAART-Highly active antiretroviral drugs, ORS-Oral
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The World Health Report has classified interventions
with cost-effectiveness ratios of less than the country’s
per capita GDP as highly cost-effective and those which
are 1–3 times the per capita GDP as cost-effective [35].
Most of the interventions we have identified in this
study have cost-effectiveness ratios which are well
below the Tanzania’s estimated GDP per capita of US$
550 [36], hence they can be considered as highly cost-
effective. On the other hand, Tanzania has a per capita
expenditure on health of about US$ 14 per year [37],
which is below the US$ 40 recommended by WHO to
finance essential health interventions [38]. This means
its ability to implement and scale-up even what can be
considered as a highly cost-effective intervention is
limited.
Our literature review shows that only a few pharma-
coeconomic studies have been conducted in Tanzania.
Nine out of the twelve studies were on drug therapies
and vaccine against infectious diseases which are respon-
sible for more than two-third of the disease burden in
sub-Saharan Africa [39]. Nine studies were published
within the last ten years, of which six are less than five
years old indicating an increasing focus on this research
area (Table 2). Antimalarial and antiretroviral drugs were
the most researched drugs, which mean that to some ex-
tent researchers have responded to the importance of
the two diseases for the burden of diseases in Tanzania
(Table 1). Half of the identified studies were on interven-
tions targeting pregnant women and children under the
age of five years, reflecting concerns for the high mortal-
ity rates for these vulnerable groups in Tanzania.Table 2 Study characteristics
Authors Year Target Interventions
Guerriero et al. [20] 2011 Injury (Bleeding Trauma Patients)
Robberstad et al. [21] 2010 HIV/AIDS (Prevention of
Mother-to-Child Transmissions)
Guerriero et al. [29] 2010 Surgical Bleeding
Hutton et al. [27] 2009 Malaria (Intermittent Prevention
Therapy in Infants)
Shim et al. [30] 2009 Rabies vaccination
Robberstad et al. [22] 2007 Cardiovascular diseases
Wiseman et al. [26] 2006 Case management of non-severe
malaria
Robberstad et al. [23] 2004 Diarrhoeal diseases
Sweat et al. [24] 2004 HIV/AIDS (Prevention of
Mother-to-Child Transmissions)
Abdulla et al. [25] 2000 Case management of non-severe
malaria
Gonzalez et al. [28] 2000 Malaria (Intermittent Prevention
Therapy in Infants)
Murray et al. [31] 1991 TuberculosisHIV/AIDS
HIV/AIDS is the number one priority health problem in
Tanzania, and affects the most productive age group ran-
ging from 15–59 years, hence impairing the country’s
economic growth [40]. About 20 per cent of the mortal-
ities for admitted patients above five years of age
recorded in Tanzania each year are due to HIV/AIDS
and Tuberculosis [41]. Our study found two pharmacoe-
conomic studies on prevention of mother-to-child trans-
mission (PMTCT) and none on case management of
HIV/AIDS.
PMTCT programs are in transition in Tanzania,
responding to the current recommendations consisting
of two prophylactic options provided by the WHO. Op-
tion A consists of zidovudine (AZT) which is initiated
on week 14 of pregnancy, followed with single dose
nevirapine (sd-NVP) plus lamivudine (3TC) at the onset
of labour until delivery. AZT and 3TC are then contin-
ued for 7 days postpartum. Option B is composed of
triple ARV drugs which are also initiated on week 14 of
pregnancy until one week after cessation of breastfeed-
ing [42]. The task of choosing which option to imple-
ment rests on individual countries and should be based
on the feasibility, acceptability, safety and costs [42].
This is a practical example where pharmacoeconomic
analysis should be used to guide medicine selection.
Tanzania has opted to implement option A [43], how-
ever, without being guided by cost-effectiveness com-
parison evidence for option A and B. An economic
evaluation study by Robberstad et al. at Haydom Lu-
theran Hospital in Northern Tanzania showed that op-
tion B was highly cost-effective in the Tanzanian settings
with incremental cost-effectiveness ratio of US$ 162 per
DALY averted. This regimen was however 40 per cent
more expensive than sd-NVP but 5 times more effective
[21]. Since option A at the time of the study was not
being implemented at the study site, they did not make
cost-effectiveness comparisons of option A and B rela-
tive to sd-NVP. Drug costs for option B relative to op-
tion A which were approximately up to five times in
2009, have been reduced significantly down to two times
by the end of 2011 [44]. WHO has recently released a
new PMTCT update advising countries to adopt the use
of option B plus, where a pregnant woman is placed on
option B for life regardless of CD4 cell count or clinical
staging [45].
Malaria
Malaria is second after HIV/AIDS on the disease burden
in Tanzania. On average about 46 per cent of all in-
patient and out-patient cases registered in the healthcare
facilities each year are due to malaria [41]. Malaria is the
leading cause of morbidity and mortality among children
under the age of five years [40,41]. Malaria during
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which is recognized as the single greatest risk factor for
neonatal and infant mortalities in sub-Saharan countries
[47]. A recent study showed that the burden of malaria
among adults has been highly underestimated. Accord-
ing to the findings of this study, malaria is also the major
cause of deaths among adult populations [48].
Our review found four pharmacoeconomic studies on
malaria, two of them being on malaria case manage-
ment. Tanzania has changed its national malaria treat-
ment policy twice over the past ten years due to drug
resistance to formerly effective antimalarials. These pol-
icy changes involved replacement of chloroquine (CQ)
with sulphadoxine-pyrimethamine (SP), which was sub-
sequently replaced by artemether-lumefantrine (ALu)
[49,50]. Both SP and ALu were at the time the most
cost-effective antimalarials compared to alternatives
which were available [25,26]. Our review of treatment
guidelines and other relevant policy documents showed
inconsistent use of pharmacoeconomic evaluations dur-
ing malaria treatment policy change. As a result the de-
cision to change to ALu unlike that of changing to SP
has been criticized for largely being based on the efficacy
rather than cost-effectiveness comparisons [51].
The other two studies were on presumptive treatment
of malaria using SP in infants (SP-IPTi) and Deltaprim
(a combination of pyrimethamine and dapsone) plus Iron
in infants and pregnant women. Studies from African
settings have shown that SP-IPTi could reduce episodes
of clinical malaria, anaemia and rates of hospitalization
in infants by 30, 21 and 38 per cent respectively [32]. As
a result SP-IPTi has been adopted by WHO since 2010
as a new malaria intervention strategy targeting infants
residing in areas with moderate to high malaria transmis-
sions, but with low resistance to SP [52]. SP-IPTi was
demonstrated to be highly cost-effective in Tanzania with
incremental cost-effectiveness ratios of US$ 1.57 (0.8-4.0)
and US $ 3.7 (1.6-12.2) per malaria episode and DALY
averted, respectively [27]. Even though Global Fund and
other donors have made financial resources available to
support the implementation of this intervention [53],
SP-IPTi has not yet been adopted in Tanzania. Studies
from the Northern and Southern areas of the country
have reported low protective efficacy results from the
use of this intervention [54,55].
Diarrhoeal diseases
Diarrhoea is ranked third on the disease burden in
Tanzania and is considered the second main cause of
deaths among children under the age of five years world-
wide after malaria [56]. Oral rehydration salts (ORS) re-
duce the duration of diarrhoea episode and replaces the
lost water and electrolytes hence preventing the occur-
rence of dehydration. When Zinc is given as an adjuncttherapy for 10–14 days, it has been proved to reduce the
duration of acute diarrhoea by 25 per cent and treat-
ment failure or death due to persistent diarrhoea by 42
per cent. It also prevents episodes of subsequent infec-
tions for up to three months [57,58]. In 2004, WHO and
UNICEF recommended that countries adopt the use of
Zinc and low osmolarity oral rehydration salts (lo-ORS)
in their revised guidelines for treatment of diarrhoea
[59]. Zinc was included in WHO model list of essential
medicines in 2005 based on the evidence of cost, effi-
cacy, safety and cost-effectiveness in the management of
diarrhoea [60].
We found one pharmacoeconomic study by Robber-
stad et al. on Zinc as adjunct therapy which reported it
to be cost-effective in Tanzania [23]. Tanzania adopted
the new diarrhoea treatment guidelines which incorpo-
rated the use of Zinc in July 2007 [61] followed by its
listing in the national essential medicine list the same
year [13]. Our review of documents revealed that a task
force committee which was composed of representatives
from the government, WHO, UNICEF, and non-
governmental organization was formed to advocate for
adoption of Zinc [61]. However there is no evidence of
whether economic evaluation was among the criteria on
which the local decision was based apart from the
WHO/UNICEF recommendation.
Injuries
Injuries/trauma and emergencies is ranked fourth on the
disease burden in Tanzania [62]. Victims of injuries/
trauma often require blood transfusions to replace the
massive amount of blood lost. Other recipients of blood
transfusion include pregnant women, patients coming
from surgery and those with anaemia. Pregnant women
in African settings who need blood transfusions during
or after delivery often suffer preventable deaths due to
shortages of blood supplies [63]. Even though blood
transfusion is considered a lifesaving intervention, it also
exposes its recipients to blood-borne viral infections
such as HIV/AIDS and Hepatitis B. In Tanzania the
average HIV/AIDS prevalence among blood donors has
been estimated to be 9 per cent [41]. Shortages of blood
supply for transfusions and risks of disease transmissions
make alternative options not requiring blood transfu-
sions more attractive.
We found two pharmacoeconomic studies on Tranex-
amic acid (TXA) – an antifibrinolytic drug which
reduces post-operative blood loss and transfusion
requirements to injury victims [64]. TXA can reduce the
risks of death due to bleeding by 21 percent if adminis-
tered within three hours after injury [34]. For elective
surgery, TXA reduces the requirement of blood transfu-
sion by one-third and the volume per transfusion by
one unit [33]. The incremental cost-effectiveness of
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was 48 US$ per LY gained [20], while the incremental cost-
effectiveness for surgical bleeding was US $ 93 per life saved
[29]. Despite being reported to be very cost-effective in
Tanzania, TXA injection is not on the national essential
medicine list, but has recently been added to the WHO’s
model list of essential medicines [65].
Tuberculosis
TB is ranked sixth on the disease burden in Tanzania in
spite of being recognized as having one of the most suc-
cessful national TB programs in the world, with a treat-
ment success rate of 88 per cent [37]. We found one
relatively old economic evaluation study by Murray et al.
which compared the cost-effectiveness of short-course
versus long-course anti-TB chemotherapies. The study
showed that short-course chemotherapy was less costly
per death averted and per LY saved when compared to
the long, 12-months chemotherapy for both hospital and
ambulatory care [31]. The short-course strategy was
found to be very cost-effective with incremental cost-
effectiveness ratio of 1–4 US$ per life year saved. In
areas with an organized healthcare system the short-
course regimen increased the cure rate by a quarter
when compared to the standard therapy [31]. Short-
course chemotherapy was already introduced in Tanzania
before the publication of the study conducted by Murray
et al. However, our review of documents showed that the
decision to adopt the use of short-course chemotherapy
was grounded on evidence of better treatment outcomes
at less costs shown by the short-course regimen in
Tanzania [66].
Cardiovascular diseases
Cardiovascular diseases are ranked tenth on disease bur-
den and are the leading causes of mortality in elderly in
Tanzania [40]. We found one pharmacoeconomic study
by Robberstad et al. who explored the cost-effectiveness
of 14 drug therapy combinations given to patients with
cardiovascular diseases. They found incremental cost-
effectiveness ratios ranging from 86 US$ to about 4,600
US$ per DALY saved, hydrochlorothiazide – a diuretic
drug, being the most cost-effective option [22]. Review
of the national essential medicine lists shows that many
of the drug therapies they studied were already on the
list but again without cost-effectiveness evidences for
their selection.
Rabies
About 5 people out of 100,000 die of rabies in Tanzania
each year [67]. Deaths due to rabies, mostly from dog
bites, can be prevented through post-exposure prophy-
laxis with anti-rabies vaccines. We found one pharma-
coeconomic study by Shim et al., on anti-rabies vaccinefor post-exposure prophylaxis which reported an incre-
mental cost-effectiveness ratio of US$ 32 and US$ 27
per QALY gained, from societal and provider perspec-
tives respectively [30]. This intervention is highly cost-
effective and if scaled-up can avert 5,000 QALYs lost
each year [30]. Anti-rabies vaccine has been on the na-
tional essential medicine list since 2007 [13], therefore
the cost-effectiveness evidence provided by the study
published by Shim et al. is too recent to have had influ-
enced the decision to include the vaccine on the national
essential medicine list.
Use of pharmacoeconomic data from other settings
With only a few pharmacoeconomic analysis studies
available for decision-makers in Tanzania, one is
tempted to deploy economic evidences from studies
conducted elsewhere. Cost-effectiveness studies are con-
text specific and generalizations must always be done
with great caution [68]. For example, healthcare costs
depend on factors such as the structure and functioning
of the healthcare systems, availability of healthcare
resources and pricing mechanisms, which can vary from
one setting to another. Effectiveness of drug therapies
on the other hand depends on their utilization and per-
formance in the real life conditions. Utilization of a drug
depends on its acceptability and perceived side effects
among the users. Therefore, before cost-effectiveness
results from one setting can be applied to inform deci-
sion making in other settings, the relevance of such con-
text specific factors should be evaluated by considering
the impact of the differences on the results and conclu-
sions. In well designed and well reported studies, such
assessments can be accommodated with sensitivity and
scenario analyses. We have seen that pharmacoeconomic
studies conducted locally are scarce; therefore we argue
that decision-makers in Tanzania sometimes can make
use of pharmacoeconomic data available from similar
African countries. However when the differences in con-
text specific factors are large, or when the sensitivity of
the results are insufficiently explored, such generaliza-
tions should not be made.
Limitations of the study
The findings of this study are only based on information
retrieved through systematic review of articles and rele-
vant policy documents, and hence must be interpreted
with care. We did not conduct any interviews to supple-
ment the information we extracted from the policy
documents which are neither readily nor consistently
available in Tanzania due to logistic challenges. We
therefore believe that our search may have not been ex-
haustive, and so there might be other policy documents
containing relevant information related to this study
which we did not manage to access.
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There are only a few pharmacoeconomic studies which
have been conducted in Tanzania and which are useful
to guide selection of essential medicines. The majority of
these studies are narrow in scope hence do not corres-
pond to drug selection challenges decision-makers are
always confronted with in priority-setting decisions. We
found little evidence suggesting that the existing phar-
macoeconomic studies had impact on the selection and
hence listing of drugs in the national essential medicine
list. While we encourage more studies on pharmacoeco-
nomic analysis to fill the existing gap, we also emphasise
the importance to assess whether decision-makers in
the drug selection committees have the ability to inter-
pret and utilise cost-effectiveness evidence when asses-
sing pharmaceuticals for inclusion in the treatment
guidelines and essential medicine list. We also encourage
Tanzanian health authorities to consider how health eco-
nomic evidence should be applied more consistently
in priority-setting decisions for selection of essential
medicines.
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